A detailed history of Hyman Charles D transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Hyman Charles D holds 800 shares of VRTX stock, worth $360,296. This represents 0.02% of its overall portfolio holdings.

Number of Shares
800
Previous 800 -0.0%
Holding current value
$360,296
Previous $334,000 11.98%
% of portfolio
0.02%
Previous 0.02%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 02, 2022

BUY
$234.96 - $292.55 $187,968 - $234,040
800 New
800 $225,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Hyman Charles D Portfolio

Follow Hyman Charles D and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hyman Charles D, based on Form 13F filings with the SEC.

News

Stay updated on Hyman Charles D with notifications on news.